Cambrex Corporation announced that it has received a warning letter from the U.S. Food and Drug Administration relating to an inspection of the Company's generic active pharmaceutical ingredient manufacturing facility located in Milan, Italy in March 2009.
The details can be read here.
No comments:
Post a Comment